Regulation of interleukin-6 and leptin in schizophrenia patients: A preliminary analysis

Clinical Psychopharmacology and Neuroscience

Volumn 12, Issue 3, 2014, Pages 209-214

  Neelamekam, Sasi ^a   Nurjono, Milawaty ^a   Lee, Jimmy ^a,b,c  

^a Research Division Institute of Mental Health   (Australia)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

Adipokines; Immune; Inflammation; Psychotic disorders

Indexed keywords

INTERLEUKIN 6; LEPTIN;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DSM-IV-TR; EFFECT SIZE; FEMALE; HUMAN; MALE; MULTIPLE REGRESSION; SCHIZOPHRENIA;

EID: 84920023012     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2014.12.3.209     Document Type: Article

References (59)

1. Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 2010;64:217-230.
2. Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2. Genome-wide association study implicates HLA-C∗01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biol Psychiatry 2012;72:620-628.
3. Walker E, Kestler L, Bollini A, Hochman KM. Schizophrenia: etiology and course. Annu Rev Psychol 2004;55:401-430.
4. Tsuang MT, Stone WS, Faraone SV. Genes, environment and schizophrenia. Br J Psychiatry Suppl 2001;40:s18-s24.
5. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006;8 Suppl 2:S3.
6. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009;50:1801-1807.
7. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009;63:257-265.
8. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
9. Zakharyan R, Boyajyan A. Inflammatory cytokine network in schizophrenia. World J Biol Psychiatry 2014;15:174-187.
10. Lord GM. Leptin as a proinflammatory cytokine. Contrib Nephro 2006;151:151-164.
11. Sentissi O, Epelbaum J, Olié JP, Poirier MF. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008;34: 1189-1199.
12. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000;68: 437-446.
13. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001;15:2565-2571.
14. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol 2005;174:3137-3142.
15. Li J, Li F, Zhao A. Inflammation and leptin. Drug Discov Today: Dis Mech 2006;3:387-393.
16. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-2800.
17. Pollmächer T. An emerging role of leptin in clinical psychiatry. In: Kordon C, Robinson I, Hanoune J, Dantzer R, Christen Y, editors. Brain somatic cross-talk and the central control of metabolism. Research and perspectives in endocrine interactions. Berlin, Heidelberg:Springer;2003. p.143-153.
18. DiLeone RJ. The influence of leptin on the dopamine system and implications for ingestive behavior. Int J Obes (Lond) 2009;33(Suppl 2):S25-S29.
19. Moulin CM, Marguti I, Peron JP, Rizzo LV, Halpern A. Impact of adiposity on immunological parameters. Arq Bras Endocrinol Metabol 2009;53:183-189.
20. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm 2013;2013:139239.
21. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007;8:21-34.
22. Martí A, Marcos A, Martínez JA. Obesity and immune function relationships. Obes Rev 2001;2:131-140.
23. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.
24. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014;105:141-150.
25. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006;6:438-446.
26. Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 2004;89:5577-5582.
27. Bruun JM, Pedersen SB, Kristensen K, Richelsen B. Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. Mol Cell Endocrinol 2002;190:91-99.
28. Granowitz EV. Transforming growth factor-beta enhances and pro-inflammatory cytokines inhibit ob gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 1997;240:382-385.
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
30. Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974;11:65-69.
31. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.
32. Wei J, Xu H, Davies JL, Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1992;51:1953-1956.
33. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994;51:1-10.
34. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kühn M, Schuld A, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999;33:407-418.
35. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 1999;37:97-106.
36. Dunjic-Kostic B, Jasovic-Gasic M, Ivkovic M, Radonjic NV, Pantovic M, Damjanovic A, et al. Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatr Danub 2013;25:55-61.
37. Frommberger UH, Bauer J, Haselbauer P, Fräulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997;247:228-233.
38. Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 2011;33:268-274.
39. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994;89:346-351.
40. Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, Klimke A, et al. Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis Treat 2005;1:171-177.
41. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006;83:461S-465S.
42. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-919; quiz 920.
43. Aronson D, Avizohar O, Levy Y, Bartha P, Jacob G, Markiewicz W. Factor analysis of risk variables associated with low-grade inflammation. Atherosclerosis 2008;200: 206-212.
44. Gispen-de Wied CC. Stress in schizophrenia: an integrative view. Eur J Pharmacol 2000;405:375-384.
45. Kiecolt-Glaser JK. Stress, food, and inflammation: psychoneuroimmunology and nutrition at the cutting edge. Psychosom Med 2010;72:365-369.
46. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949.
47. Kluge M, Schuld A, Schacht A, Himmerich H, Dalal MA, Wehmeier PM, et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009;34:118-128.
48. Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997;26:221-225.
49. Lü LX, Guo SQ, Chen W, Li Q, Cheng J, Guo JH. Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia. Di Yi Jun Yi Da Xue Xue Bao 2004;24:1251-1254.
50. Pae CU, Yoon CH, Kim TS, Kim JJ, Park SH, Lee CU, et al. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int Immunopharmacol 2006;6:666-671.
51. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology 2009;59:123-129.
52. Lin CC, Chang CM, Chang PY, Huang TL. Increased interleukin-6 level in Taiwanese schizophrenic patients. Chang Gung Med J 2011;34:375-381.
53. Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura G, Pioli R, Boin F, et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000;10:119-124.
54. Jin H, Meyer JM, Mudaliar S, Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008;100:70-85.
55. Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013;42:135-145.
56. Davis C, Mudd J, Hawkins M. Neuroprotective effects of leptin in the context of obesity and metabolic disorders. Neurobiol Dis 2014. doi:10.1016/j.nbd.2014.04.012. [Epub ahead of print]
57. Tourjman V, Koué MÈ, Kouassi E, Potvin S. Immunomodulatory effects of antipsychotics on inflammatory mediators: a review. Adv Biosci Biotechnol 2012;3:551-565.
58. Murashita M, Inoue T, Kusumi I, Nakagawa S, Itoh K, Tanaka T, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci 2007;61:54-58.
59. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012;37:1901-1911.